Microwave ablation followed by immediate biopsy in the treatment of non-small cell lung cancer. (1st January 2019)

• Record Type: Journal Article
• Authors: Wei, Zhigang; Wang, Qiaoxia; Ye, Xin; Yang, Xia; Huang, Guanghui; Li, Wenhong; Wang, Jiao; Han, Xiaoying; Meng, Min; Yang, Ni; Li, Qingyu
• Is Part Of: International journal of hyperthermia. Volume 35:Number 1(2018)
• Page Start: 262
• Page End: 268
• Publication Date: 2019-01-01
• Subjects: Non-small cell lung cancer -- microwave ablation -- changes in pathology; Thermotherapy -- Periodicals; 615.832
• DOI: 10.1080/02656736.2018.1494856
• Languages: English
• ISSNs: 0265-6736

Abstract

Abstract: Background : To evaluate the efficacy and safety of microwave ablation (MWA) followed by immediate biopsy in the treatment of non-small cell lung cancer (NSCLC) and to clarify whether pathology changes can predict treatment responses and patient survival. Methods : Patients with pathologically confirmed NSCLC pre-ablation were treated with MWA, and immediate biopsy was carried out right after ablation in one procedure. Pathology changes were categorized according to the pre- and postablation pathology: Group A, same histology type; Group B, paired histology type with burning degeneration; Group C, no definite histology type; Group D, no definite cancer cells. The internal correlations between pathology changes and baseline characteristics, responses to MWA and survival were evaluated. Results : A total of 68 patients were enrolled in the study, of which 19, 28, 11 and 10 patients were classified into Group A, Group B, Group C and Group D, respectively. In total, 85.3 and 69.1% patients were diagnosed with malignant tumors and the same pathology type, respectively. No significant difference in clinical-pathologic characteristics or response to MWA between the groups was observed. Upon combining Groups A, B and C, Group D exhibited longer progression-free survival (PFS) (Groups A + B + C versus Group D, 11.7 months, 95% CI 9.6–13.7 versus 26.6 months, 95% CI 19.0–34.2, p = .253) and overall survival (OS) (15.9 months, 95% CI 14.2–17.5, versus 29.8 months, 95% CI, 24.3–35.3, p = .395), although no significant differences were observed. Complications were identified in 63 (92.6%), of which 17 (25.0%) patients had major complications. Conclusions : Immediate biopsy post-MWA can distinguish cancer cells or histology types in most cases of NSCLC. However, pathology changes pre- and postablation could not predict the response to MWA and patient survival.